No label defined (Q3201446)

From EU Knowledge Graph
Revision as of 00:23, 13 October 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): BACKGROUND: PET/CT technology is an effective and fundamental tool for the diagnosis and monitoring of oncological and neurological diseases. PET cancer studies in Spain account for 12.5 % of the dose due to nuclear medicine studies, the dose being doubled when considering CT. A reduction in these doses would have a major impact on the overall collective dose. SCENARIO: In PET/CT studies it is possible to reduce the radiation dose received by th...)
Jump to navigation Jump to search
Project Q3201446 in Spain
Language Label Description Also known as
English
No label defined
Project Q3201446 in Spain

    Statements

    0 references
    0 references
    20,750.0 Euro
    0 references
    41,500.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2017
    0 references
    31 March 2020
    0 references
    UNIVERSIDAD DE NAVARRA
    0 references

    42°49'6.42"N, 1°38'39.34"W
    0 references
    31201
    0 references
    ANTECEDENTES: La tecnología PET/CT es un herramienta eficaz y fundamental para el diagnóstico y seguimiento de enfermedades oncológicas y neurológicas. Los estudios oncológicos PET en España suponen el 12.5% de la dosis debida a los estudios de Medicina Nuclear, duplicándose la dosis al considerar el CT. Una reducción de dichas dosis tendría un gran impacto en la dosis colectiva global. HIPÓTESIS: En los estudios PET/CT es posible reducir la dosis de radiación recibida por el paciente sin perder capacidad diagnóstica. Se puede realizar el estudio de optimización en un equipo aplicando distintos modos de reconstrucción tomográfica para simular una diversidad de modelos de tomógrafos con distintas prestaciones. OBJETIVOS: Reducir y optimizar la dosis de radiación que recibe el paciente en los procedimientos diagnósticos PET/CT de estudios oncológicos de cuerpo entero con 18F-FDG y con 11C-Colina y en estudios neurológicos con 18F-FDG, 11C-Metionina, 18F-DOPA y con radiofármacos fluorados marcadores de la placa beta-amiloide. METODOLOGÍA: Variando la reconstrucción tomográfica PET se simulan estudios de 4 modelos de equipos PET/CT: PET básico, PET con PSF, PET con TOF, PET con PSF y TOF. El proceso de optimización se realiza (1) manteniendo la calidad de la imagen tanto en CT como en PET, y (2) utilizando maniquíes antropomórficos, de cuerpo y cerebro, que simulan la atenuación del paciente en CT y reproducen los contrastes PET de las lesiones. Finalmente se valida la reducción de dosis con un maniquí que simula diversos órganos y se cuantifica el impacto de los protocolos optimizados en estudios PET de pacientes. (Spanish)
    0 references
    BACKGROUND: PET/CT technology is an effective and fundamental tool for the diagnosis and monitoring of oncological and neurological diseases. PET cancer studies in Spain account for 12.5 % of the dose due to nuclear medicine studies, the dose being doubled when considering CT. A reduction in these doses would have a major impact on the overall collective dose. SCENARIO: In PET/CT studies it is possible to reduce the radiation dose received by the patient without losing diagnostic capacity. The optimisation study can be performed on a team using different modes of tomographic reconstruction to simulate a diversity of tomograph models with different performances. OBJECTIVES: Reduce and optimise the radiation dose received by the patient in the PET/CT diagnostic procedures of whole-body oncology studies with 18F-FDG and 11C-Colina and in neurological studies with 18F-FDG, 11C-Methionine, 18F-DOPA and fluorinated radiopharmaceutical markers of the beta-amyloid plaque. METHODOLOGY: Varying PET tomographic reconstruction simulates studies of 4 models of PET/CT equipment: Basic PET, PET with PSF, PET with TOF, PET with PSF and TOF. The optimisation process is performed (1) maintaining image quality in both CT and PET, and (2) using anthropomorphic, body and brain mannequins that simulate the patient’s attenuation in CT and reproduce the PET contrasts of the lesions. Finally, dose reduction is validated with a manikin that simulates various organs and quantifies the impact of optimised protocols in PET studies of patients. (English)
    13 October 2021
    0 references
    Pamplona/Iruña
    0 references

    Identifiers

    PI16_00270
    0 references